| Drug-Target Information | ||||||||
|---|---|---|---|---|---|---|---|---|
| Drug Name | Target Name | Drug Type | Target Type | Source | Drug MeSHID | Interaction Score | Drug Status | Target Action |
| carbamazepine | neuronal acetylcholine receptor subunit alpha-4 | small molecule | NA | drugbank | Bipolar Disorder[MeSHID:D001714] Restless Legs Syndrome[MeSHID:D012148] Epilepsy[MeSHID:D004827] Trigeminal Neuralgia[MeSHID:D014277] Pain[MeSHID:D010146] Substance Withdrawal Syndrome[MeSHID:D013375] Seizures Focal[MeSHID:D012640] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Stomach[MeSHID:D013270] Adenocarcinoma[MeSHID:D000230] Diabetes Mellitus Insulin-Dependent[MeSHID:D003922] |
NA | approved,investigational | unknown |
| carbamazepine | nuclear receptor subfamily 1 group i member 2 | small molecule | NA | drugbank , DGIDB | Bipolar Disorder[MeSHID:D001714] Restless Legs Syndrome[MeSHID:D012148] Epilepsy[MeSHID:D004827] Trigeminal Neuralgia[MeSHID:D014277] Pain[MeSHID:D010146] Substance Withdrawal Syndrome[MeSHID:D013375] Seizures Focal[MeSHID:D012640] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Stomach[MeSHID:D013270] Adenocarcinoma[MeSHID:D000230] Diabetes Mellitus Insulin-Dependent[MeSHID:D003922] |
0.05 | approved,investigational | activator |
| carbamazepine | voltage-gated sodium channel alpha subunit | small molecule | NA | drugbank , DGIDB | Bipolar Disorder[MeSHID:D001714] Restless Legs Syndrome[MeSHID:D012148] Epilepsy[MeSHID:D004827] Trigeminal Neuralgia[MeSHID:D014277] Pain[MeSHID:D010146] Substance Withdrawal Syndrome[MeSHID:D013375] Seizures Focal[MeSHID:D012640] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Stomach[MeSHID:D013270] Adenocarcinoma[MeSHID:D000230] Diabetes Mellitus Insulin-Dependent[MeSHID:D003922] |
0.02 | approved,investigational | inhibitor,blocker |
| carbamazepine | voltage-gated sodium channel alpha subunit | small molecule | NA | drugbank , DGIDB | Bipolar Disorder[MeSHID:D001714] Restless Legs Syndrome[MeSHID:D012148] Epilepsy[MeSHID:D004827] Trigeminal Neuralgia[MeSHID:D014277] Pain[MeSHID:D010146] Substance Withdrawal Syndrome[MeSHID:D013375] Seizures Focal[MeSHID:D012640] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Stomach[MeSHID:D013270] Adenocarcinoma[MeSHID:D000230] Diabetes Mellitus Insulin-Dependent[MeSHID:D003922] |
0.02 | approved,investigational | inhibitor,blocker |
| carbamazepine | voltage-gated sodium channel alpha subunit | small molecule | NA | drugbank , DGIDB | Bipolar Disorder[MeSHID:D001714] Restless Legs Syndrome[MeSHID:D012148] Epilepsy[MeSHID:D004827] Trigeminal Neuralgia[MeSHID:D014277] Pain[MeSHID:D010146] Substance Withdrawal Syndrome[MeSHID:D013375] Seizures Focal[MeSHID:D012640] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Stomach[MeSHID:D013270] Adenocarcinoma[MeSHID:D000230] Diabetes Mellitus Insulin-Dependent[MeSHID:D003922] |
0.37 | approved,investigational | inhibitor |
| carbamazepine | voltage-gated sodium channel alpha subunit | small molecule | NA | drugbank , DGIDB | Bipolar Disorder[MeSHID:D001714] Restless Legs Syndrome[MeSHID:D012148] Epilepsy[MeSHID:D004827] Trigeminal Neuralgia[MeSHID:D014277] Pain[MeSHID:D010146] Substance Withdrawal Syndrome[MeSHID:D013375] Seizures Focal[MeSHID:D012640] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Stomach[MeSHID:D013270] Adenocarcinoma[MeSHID:D000230] Diabetes Mellitus Insulin-Dependent[MeSHID:D003922] |
0.37 | approved,investigational | inhibitor,blocker |
| carbamazepine | voltage-gated sodium channel alpha subunit | small molecule | NA | drugbank , DGIDB | Bipolar Disorder[MeSHID:D001714] Restless Legs Syndrome[MeSHID:D012148] Epilepsy[MeSHID:D004827] Trigeminal Neuralgia[MeSHID:D014277] Pain[MeSHID:D010146] Substance Withdrawal Syndrome[MeSHID:D013375] Seizures Focal[MeSHID:D012640] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Stomach[MeSHID:D013270] Adenocarcinoma[MeSHID:D000230] Diabetes Mellitus Insulin-Dependent[MeSHID:D003922] |
0.11 | approved,investigational | inhibitor,blocker |
| carbamazepine | voltage-gated sodium channel alpha subunit | small molecule | NA | drugbank , DGIDB | Bipolar Disorder[MeSHID:D001714] Restless Legs Syndrome[MeSHID:D012148] Epilepsy[MeSHID:D004827] Trigeminal Neuralgia[MeSHID:D014277] Pain[MeSHID:D010146] Substance Withdrawal Syndrome[MeSHID:D013375] Seizures Focal[MeSHID:D012640] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Stomach[MeSHID:D013270] Adenocarcinoma[MeSHID:D000230] Diabetes Mellitus Insulin-Dependent[MeSHID:D003922] |
0.11 | approved,investigational | inhibitor |
| carbamazepine | voltage-gated sodium channel alpha subunit | small molecule | NA | drugbank , DGIDB | Bipolar Disorder[MeSHID:D001714] Restless Legs Syndrome[MeSHID:D012148] Epilepsy[MeSHID:D004827] Trigeminal Neuralgia[MeSHID:D014277] Pain[MeSHID:D010146] Substance Withdrawal Syndrome[MeSHID:D013375] Seizures Focal[MeSHID:D012640] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Stomach[MeSHID:D013270] Adenocarcinoma[MeSHID:D000230] Diabetes Mellitus Insulin-Dependent[MeSHID:D003922] |
0.02 | approved,investigational | inhibitor,blocker |
| carbamazepine | voltage-gated sodium channel alpha subunit | small molecule | NA | drugbank , DGIDB | Bipolar Disorder[MeSHID:D001714] Restless Legs Syndrome[MeSHID:D012148] Epilepsy[MeSHID:D004827] Trigeminal Neuralgia[MeSHID:D014277] Pain[MeSHID:D010146] Substance Withdrawal Syndrome[MeSHID:D013375] Seizures Focal[MeSHID:D012640] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Stomach[MeSHID:D013270] Adenocarcinoma[MeSHID:D000230] Diabetes Mellitus Insulin-Dependent[MeSHID:D003922] |
0.02 | approved,investigational | inhibitor,blocker |
| carbamazepine | voltage-gated sodium channel alpha subunit | small molecule | NA | drugbank , DGIDB | Bipolar Disorder[MeSHID:D001714] Restless Legs Syndrome[MeSHID:D012148] Epilepsy[MeSHID:D004827] Trigeminal Neuralgia[MeSHID:D014277] Pain[MeSHID:D010146] Substance Withdrawal Syndrome[MeSHID:D013375] Seizures Focal[MeSHID:D012640] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Stomach[MeSHID:D013270] Adenocarcinoma[MeSHID:D000230] Diabetes Mellitus Insulin-Dependent[MeSHID:D003922] |
0.12 | approved,investigational | inhibitor,blocker |
| carbamazepine | voltage-gated sodium channel alpha subunit | small molecule | NA | drugbank , DGIDB | Bipolar Disorder[MeSHID:D001714] Restless Legs Syndrome[MeSHID:D012148] Epilepsy[MeSHID:D004827] Trigeminal Neuralgia[MeSHID:D014277] Pain[MeSHID:D010146] Substance Withdrawal Syndrome[MeSHID:D013375] Seizures Focal[MeSHID:D012640] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Stomach[MeSHID:D013270] Adenocarcinoma[MeSHID:D000230] Diabetes Mellitus Insulin-Dependent[MeSHID:D003922] |
0.12 | approved,investigational | inhibitor |
| carbamazepine | voltage-gated sodium channel alpha subunit | small molecule | NA | drugbank , DGIDB | Bipolar Disorder[MeSHID:D001714] Restless Legs Syndrome[MeSHID:D012148] Epilepsy[MeSHID:D004827] Trigeminal Neuralgia[MeSHID:D014277] Pain[MeSHID:D010146] Substance Withdrawal Syndrome[MeSHID:D013375] Seizures Focal[MeSHID:D012640] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Stomach[MeSHID:D013270] Adenocarcinoma[MeSHID:D000230] Diabetes Mellitus Insulin-Dependent[MeSHID:D003922] |
0.02 | approved,investigational | inhibitor,blocker |
| carbamazepine | voltage-gated sodium channel alpha subunit | small molecule | NA | drugbank , DGIDB | Bipolar Disorder[MeSHID:D001714] Restless Legs Syndrome[MeSHID:D012148] Epilepsy[MeSHID:D004827] Trigeminal Neuralgia[MeSHID:D014277] Pain[MeSHID:D010146] Substance Withdrawal Syndrome[MeSHID:D013375] Seizures Focal[MeSHID:D012640] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Stomach[MeSHID:D013270] Adenocarcinoma[MeSHID:D000230] Diabetes Mellitus Insulin-Dependent[MeSHID:D003922] |
0.02 | approved,investigational | inhibitor,blocker |
| carbamazepine | voltage-gated sodium channel alpha subunit | small molecule | NA | drugbank , DGIDB | Bipolar Disorder[MeSHID:D001714] Restless Legs Syndrome[MeSHID:D012148] Epilepsy[MeSHID:D004827] Trigeminal Neuralgia[MeSHID:D014277] Pain[MeSHID:D010146] Substance Withdrawal Syndrome[MeSHID:D013375] Seizures Focal[MeSHID:D012640] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Stomach[MeSHID:D013270] Adenocarcinoma[MeSHID:D000230] Diabetes Mellitus Insulin-Dependent[MeSHID:D003922] |
0.02 | approved,investigational | inhibitor,blocker |
| click here to return to the previous page | ||||||||